Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 223

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 223
---
1/23/2024 |     | £              | 0.004 |     | 1/23/2034  |
| Stephen Parker (1)        |     |           | 57,600,000 |     | 1/23/2024 |     | £              | 0.004 |     | 1/23/2034  |

___________

| (1) | The stock options vest in the following 25% of the options vest 12                                                                              
 months after the grant date, and the remaining options have subsequently vested, or will vest, in 12 equal quarterly tranches over a subsequent 
 three-year period.                                                                                                                              |

All stock options were granted
with an exercise price at or above market value on the date of grant.

Deed of Indemnity

Under a deed poll declared
by the Company on August 5, 2015, or a Deed of Indemnity, the Board of Directors and our Company Secretary are indemnified against costs
and liabilities incurred in connection with their office, other than any liability owed by such person to the Company itself (or any of
its associated entities) and other than indemnification for liabilities in certain circumstances, which are prohibited by virtue of the
Companies Act. The Deed of Indemnity provides that a director may also be lent sums to finance any relevant defense costs, provided that,
in the event such proceedings involve criminal or civil matters in which the person is convicted or has a judgment made against him or
her, then such loan must be repaid.

Letters of Appointment

Each non-executive director
(other than Dr. Parker) has been appointed to serve on our Board of Directors pursuant to a letter of appointment. The initial term of
appointment for each director is three years, unless terminated earlier by either party upon one month’s prior notice or in accordance
with the terms of the letters of appointment. The appointment is subject to our articles of association, and is subject to confirmation
at any annual general meeting of the Company.

| 110 |

Each non-executive director
(other than Dr. Parker) was paid an annual fee of £40,000 in 2024, which covers all duties, including committee service or service
on the board of a Biodexa subsidiary, with the exception of committee chairmanships and certain additional responsibilities, such as taking
on the role of senior independent director. This amount may be changed from time to time. In addition, we